Spread Pricing Explained: The Ultimate Guide to PBMs, Drug Costs, and Your Rights

LEGAL DISCLAIMER: This article provides general, informational content for educational purposes only. It is not a substitute for professional legal advice from a qualified attorney. Always consult with a lawyer for guidance on your specific legal situation.

Imagine you hire a general contractor to manage your kitchen renovation. You agree on a budget, and the contractor bills you $5,000 for the plumbing work. You pay it, assuming that's the cost of the plumber. Later, you discover the contractor only paid the actual plumber $3,500 and pocketed the $1,500 difference without telling you. That hidden, extra profit is the “spread.” In the world of healthcare, spread pricing is this exact practice, but with your prescription drugs. An intermediary, known as a pharmacy_benefit_manager (PBM), charges your health plan (e.g., your employer) one price for a medication, pays the pharmacy a lower price, and keeps the difference—the spread—as profit. This often happens without the health plan’s full knowledge of the size of the spread, driving up healthcare costs for everyone.

• Key Takeaways At-a-Glance:
  • The Hidden Markup: Spread pricing is the difference between what a Pharmacy Benefit Manager (PBM) charges a health plan for a drug and the lower amount it reimburses the pharmacy that actually provides it. pharmacy_benefit_manager.
  • Direct Impact on You: Spread pricing can directly increase the costs of your employer-sponsored or government health plan, which can lead to higher premiums, deductibles, and co-pays for you and your family. health_insurance.
  • The Core Legal Issue: The central controversy around spread pricing revolves around a lack of transparency and a potential breach of the PBM's fiduciary_duty to act in the best financial interest of the health plan and its members.

The concept of spread pricing didn't emerge from a single law or court case. Instead, it grew in the shadows of the American healthcare system's evolution. In the 1980s and 90s, as prescription drug costs began to skyrocket, employers and insurance companies sought help managing their pharmacy benefits. This gave rise to the Pharmacy Benefit Manager, or PBM. Initially, PBMs were seen as simple claims processors and expert negotiators. Their stated goal was to use their massive purchasing power to negotiate lower drug prices from manufacturers and create efficient pharmacy networks. They were hired as allies to control costs. However, over time, the PBM business model evolved. The three largest PBMs—CVS Caremark, Express Scripts, and OptumRx—grew to control nearly 80% of the market. With this immense market power, their revenue models became more complex and opaque. Instead of just charging a transparent administrative fee, they developed multiple streams of income, including manufacturer rebates and, most controversially, spread pricing. The practice became particularly prominent in state medicaid programs, where government oversight was sometimes less stringent. States hired PBMs to manage their pharmacy benefits, hoping to save taxpayer money. But investigative reports, beginning in the late 2010s in states like Ohio and Arkansas, uncovered that PBMs were extracting hundreds of millions of dollars through spread pricing, often targeting generic drugs where the potential for a large spread was greatest. This public exposure triggered a wave of state-level audits, legislative reforms, and a national conversation about PBM transparency that continues to this day.

There is no single federal law that says, “Spread pricing is illegal.” Instead, the practice is governed by a complex web of federal and state laws that touch on contract law, insurance regulation, and fiduciary responsibilities.

• Employee Retirement Income Security Act of 1974 (erisa): For the vast majority of Americans with employer-sponsored health insurance, ERISA is the most important law. ERISA requires that plan fiduciaries—including those who manage pharmacy benefits—act solely in the interest of plan participants. A central legal question is whether a PBM, by maximizing its own profit through non-transparent spread pricing, violates this fiduciary_duty. The department_of_labor, which enforces ERISA, has issued guidance suggesting that plan sponsors (your employer) have a duty to monitor PBMs to ensure their compensation is “reasonable” and their practices are not harming the plan.
• The Consolidated Appropriations Act, 2021 (consolidated_appropriations_act_2021): This massive spending bill contained a crucial provision impacting PBMs. It requires health plans and their service providers (including PBMs) to disclose detailed cost and compensation information to the plan sponsor. This was a major step toward piercing the veil of PBM secrecy, empowering employers to ask tough questions about where their money is going and to identify practices like spread pricing.
• State “PBM-Transparency” Laws: Frustrated by rising costs and a lack of federal action, dozens of states have passed their own laws to regulate PBMs. These laws vary widely but often include provisions that:
  • Ban spread pricing entirely within state-managed Medicaid plans.
  • Require PBMs to obtain a state license and be regulated by the state's Department of Insurance.
  • Mandate that PBMs disclose cost information, including the sources of their revenue.
  • Prohibit “gag clauses” that prevent pharmacists from telling patients about cheaper, cash-price alternatives for their medication.

How spread pricing is treated depends heavily on where you live and what kind of health plan you have. Below is a comparison of the regulatory landscape at the federal level and in four key states.

Understanding how spread pricing works requires following the money through a series of transactions that are deliberately complex. Let's break it down into its core components.

It all starts with a contract between a health plan (like your employer or a state Medicaid agency) and a PBM. The health plan hires the PBM to manage its prescription drug benefits. This contract is the most critical document, yet it is often dense and favors the PBM. It outlines how the PBM will be paid. In a spread pricing model (often called a “traditional” or “rebate-retention” model), the contract might not explicitly define or limit the spread. Instead, it will list guaranteed drug prices for the health plan without disclosing what the PBM will actually pay the pharmacies.

The PBM creates a network of pharmacies that plan members can use. To be in this network, pharmacies must agree to the PBM's terms, including its reimbursement rates. These rates are determined by complex, PBM-created price lists, most notably the Maximum Allowable Cost (MAC) list.

• A Real-World Example: Let's say you go to your local pharmacy to pick up a 30-day supply of a generic cholesterol medication.
  • The pharmacy submits a claim to the PBM.
  • The PBM's system checks its maximum_allowable_cost_(mac)_lists and determines it will pay the pharmacy $15 for this drug.

Now, the PBM turns around and bills your health plan for the same prescription. Because their contract allows it, the PBM doesn't bill the plan the $15 it paid the pharmacy. Instead, it bills the health plan a higher, pre-negotiated price.

• Continuing the Example:
  • The PBM bills your employer's health plan $55 for that same cholesterol medication.

The spread is the difference between these two transactions. It is pure profit for the PBM, earned simply for acting as the intermediary.

• The Final Math:
  • Amount Billed to Health Plan: $55
  • Amount Paid to Pharmacy: -$15
  • The Spread (PBM Profit): $40

This $40 was extracted from the healthcare system on a single, common generic drug, without the PBM ever touching the physical product. When multiplied by millions of prescriptions, this practice can generate billions of dollars in revenue for PBMs, all while driving up the costs for the health plan sponsor.

• The Pharmacy Benefit Manager (PBM): The central player. Their motivation is to maximize profit. In a spread pricing model, this is achieved by creating the largest possible gap between what they collect from the health plan and what they pay the pharmacy.
• The Health Plan Sponsor: This is typically an employer, a union, or a government agency (like Medicaid). Their motivation is to provide affordable, quality health benefits to their members. They are often at an information disadvantage, relying on the PBM's expertise and data.
• The Pharmacy: Often a small, independent pharmacy, but also includes large chains. Their motivation is to be reimbursed fairly for the drugs they dispense and the services they provide. They are often “price takers,” forced to accept the PBM's terms to stay in-network and serve their customers. Spread pricing squeezes their already thin profit margins.
• The Patient/Employee: You. Your motivation is to get the medicine you need at the lowest possible out-of-pocket cost. While spread pricing is invisible to you at the pharmacy counter, it drives up the overall cost of your health plan, leading to higher premiums and deductibles over time.
• Government Regulators: Includes state Departments of Insurance and the federal department_of_labor. Their role is to enforce the law, protect consumers, and ensure markets are fair. They are increasingly active in investigating and regulating PBM practices.

If you are a business owner, a benefits manager, or an employee concerned about rising healthcare costs, you are not powerless. Understanding spread pricing is the first step toward taking control.

1. Find Your PBM Contract: If you are a plan sponsor, this is your most important tool. Locate the PBM Services Agreement.
2. Look for Key Language: Search for terms like “traditional pricing,” “rebate retention,” or pricing definitions that reference Average Wholesale Price (AWP) discounts. Be wary of contracts that do not explicitly state a “pass-through” or “transparent” model.
3. Identify the Pricing Model: Your goal is to determine if you are in a spread pricing model or a transparent, pass-through model where the PBM simply passes along the actual pharmacy cost and charges a flat administrative fee. If the contract is unclear, that is a major red flag.

1. Request a Full Claims Report: As a plan sponsor under the consolidated_appropriations_act_2021, you have the right to detailed data. Request a report that shows, on a per-claim basis:
   • The amount your plan was charged for each drug.
   • The amount the pharmacy was reimbursed for that same drug.
2. Calculate the Spread: With this data, you or a consultant can calculate the difference. If there is a consistent, significant gap, you have identified spread pricing. Don't be surprised if the PBM is resistant to providing this level of detail; be persistent.

1. Research Pass-Through Pricing: In a pass-through_pricing model, the PBM agrees to charge you exactly what it pays the pharmacy. Their profit comes from a transparent, flat fee (e.g., per-employee-per-month or per-claim). This aligns their interests with yours: to get the lowest possible net cost.
2. Talk to Fiduciary PBMs: A new generation of “transparent” or “fiduciary” PBMs is emerging. These companies build their entire business model on transparency and contractually agree to act in your best financial interest, eliminating spread pricing and passing 100% of manufacturer rebates back to you.

1. Engage a Benefits Consultant: A knowledgeable, independent benefits consultant can analyze your claims data, identify hidden costs, and help you negotiate a better contract or find a new PBM.
2. Seek Legal Counsel: If you believe your PBM has not been transparent or may have violated its fiduciary_duty under erisa, consult with an attorney specializing in employee benefits law. They can advise you on your rights and potential courses of action.

• PBM Services Agreement: This is the master contract. Pay close attention to the sections on pricing, definitions, auditing rights, and data disclosure. Vague language is a warning sign.
• Pharmacy Claims Data File: This is the raw data that tells the true story. It should include fields like National Drug Code (NDC), quantity dispensed, amount charged to the plan, and amount reimbursed to the pharmacy. This is the evidence you need to uncover spread pricing.
• Annual PBM Transparency Reports: Under new laws, PBMs may be required to provide annual reports on their revenue sources, including rebates and other fees. Demand these reports and scrutinize them carefully.

• The Backstory: The State of Ohio hired a consultant to analyze its Medicaid managed care pharmacy spending. The state was paying PBMs billions to manage drug benefits for its most vulnerable residents.
• The Legal Question: Were PBMs saving the state money, as they claimed, or were they secretly profiting at the taxpayers' expense?
• The Findings: The resulting report was a bombshell. It revealed that PBMs charged the state $224 million more for drugs than they paid pharmacies in a single year—a spread of 8.8%. This enormous hidden cost was a primary driver of the state's pharmacy spending.
• Impact on You Today: Ohio's investigation became a national story, shining a bright light on spread pricing. It emboldened other states to conduct their own audits and triggered a wave of state-level reforms to ban the practice in Medicaid. It proved that asking for the data and auditing PBMs is a powerful tool for change.

• The Backstory: The State of Arkansas passed a law (Act 900) to regulate PBM reimbursement rates to pharmacies, aiming to prevent PBMs from paying pharmacies less than their acquisition cost for a drug. The PCMA, the PBM industry's lobbying group, sued, arguing that erisa preempted (i.e., overruled) the state's ability to pass such a law.
• The Legal Question: Can states regulate the business practices of PBMs, or does the federal ERISA law prevent them from doing so?
• The Court's Holding: In a unanimous 8-0 decision, the u.s._supreme_court ruled in favor of Arkansas. The Court held that the Arkansas law was a form of cost regulation, which falls within traditional state police powers, and did not improperly interfere with the administration of ERISA plans.
• Impact on You Today: This was a monumental victory for PBM regulation. The `rutledge_v_pcma` decision affirmed that states have significant power to regulate PBMs to protect their citizens and local businesses. It has opened the door for states across the country to pass more aggressive PBM transparency and anti-abuse laws.

The central debate over spread pricing is a clash of two narratives.

• The PBM Argument: PBMs argue that spread pricing is just one part of a complex “value proposition.” They claim that their ability to generate revenue from various sources (including spreads and rebates) allows them to offer lower overall premiums and administrative fees to health plans. They position it as a legitimate payment for their services in managing risk and creating cost-effective networks.
• The Critic's Argument: Critics, including pharmacy groups, patient advocates, and many plan sponsors, argue that spread pricing is an exploitative practice that thrives on opacity. They contend it creates perverse incentives: a PBM may favor a high-cost drug with a large spread potential over a more clinically effective, lower-cost alternative. They argue that it inflates U.S. healthcare spending and harms both patients and pharmacies.

This debate is currently playing out in state legislatures and in Congress, with growing bipartisan momentum for federal legislation that would mandate transparency and curb the most problematic PBM practices.

The future of spread pricing looks increasingly tenuous, driven by two powerful forces.

• Technology and Data Analytics: In the past, PBMs held all the cards because they controlled the data. Today, powerful data analytics platforms allow benefits consultants and plan sponsors to sift through millions of claims and instantly identify the spread. This technological shift is eroding the information asymmetry that allowed spread pricing to flourish. As more employers see the hard numbers, they are demanding a move to fully transparent, pass-through models.
• Political and Social Will: What was once an obscure industry issue is now a topic of mainstream news and political debate. Voters are angry about high drug costs, and policymakers on both sides of the aisle see PBM reform as a popular and necessary step. We can expect to see continued federal efforts to enforce transparency, potentially banning spread pricing in certain federal programs (like Medicare Part D) and creating a national framework for PBM oversight that builds on the successes seen in states like Ohio and Arkansas. The era of the “black box” PBM model is slowly but surely coming to an end.

• average_wholesale_price_(awp): A benchmark price for drugs, often criticized as being inflated, which PBMs historically used to negotiate discounts.
• clawback: A practice where a PBM forces a pharmacy to return a portion of its reimbursement for a drug, often after the point of sale.
• consolidated_appropriations_act_2021: A major federal law that includes provisions requiring PBMs to disclose more cost and compensation information to health plans.
• department_of_labor: The federal agency responsible for enforcing ERISA and protecting employee benefit plans.
• erisa: The Employee Retirement Income Security Act of 1974, the primary federal law governing private-sector employee benefit plans, including most employer-sponsored health insurance.
• fiduciary_duty: A legal obligation to act in the best financial interest of another party. ERISA imposes this duty on those who manage employee benefit plans.
• formulary: A list of prescription drugs covered by a health plan, often developed and managed by a PBM.
• health_insurance: A contract that requires an insurer to pay some or all of a person's healthcare costs in exchange for a premium.
• maximum_allowable_cost_(mac)_lists: PBM-created price lists that set the maximum reimbursement amount for generic drugs and other multi-source medications.
• medicaid: A joint federal and state program that helps with medical costs for some people with limited income and resources.
• pass-through_pricing: A transparent PBM pricing model where the health plan pays the PBM the exact same amount that the PBM pays the pharmacy, with the PBM's profit coming from a clear administrative fee.
• pharmacy_benefit_manager: A third-party administrator of prescription drug programs for health plans.

• healthcare_law
• fiduciary_duty
• contract_law
• administrative_law
• consumer_protection
• erisa
• rutledge_v_pcma